Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine - The Raffaeli Detoxification Model

Journal of Opioid Management

Volumn 7, Issue 1, 2011, Pages 21-26

  Raffaeli, William ^a   Righetti, Donatella ^a   Sarti, Donatella ^a   Balestri, Marco ^a   Ferioli, Isabella ^a   Monterubbianesi, Maria Cristina ^a   Caminiti, Alessandro ^a  

^a Infermi Hospital   (Italy)

Author keywords

Abstinence symptoms; Detoxification; Intrathecal therapy; Opioid; Ziconotide

Indexed keywords

BUPIVACAINE; CLONIDINE; KETOPROFEN; LORAZEPAM; MORPHINE; OMEGA CONOTOXIN MVIIA; TRAMADOL;

ADULT; AGED; ANALGESIA; ANXIETY DISORDER; ARTICLE; CHILL; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG DETOXIFICATION; DRUG TRANSFORMATION; FEMALE; HOT FLUSH; HUMAN; ITALY; MALE; NEUROPATHIC PAIN; OPEN STUDY; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIMARY MEDICAL CARE; PROCESS MODEL; PROSPECTIVE STUDY; RAFFAELI DETOXIFIOCATION MODEL; RESTLESSNESS; TREMOR; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

AGED; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; MORPHINE; OMEGA-CONOTOXINS; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 79952924735     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0045     Document Type: Article

References (22)

1. Breivik H, Collett B, Ventafridda V, et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4): 287-333.
2. Verhaak PFM, Kerssens JJ, Dekker J, et al.: Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain. 1998; 77: 231-239. (Pubitemid 28451511)
3. Raffaeli W, Andruccioli J, Righetti D, et al.: Intraspinal therapy for the treatment of chronic pain: A review of the literature between 1990 and 2005 and suggested protocol for its rational and safe use. Neuromodulation. 2006; 9(4): 290-308.
4. Raffaeli W, Righetti D, Caminiti A, et al.: Implantable intrathecal pumps for the treatment of noncancer chronic pain in elderly population: Drug dose and clinical efficacy. Neuromodulation. 2008; 11(1): 33-39.
5. Smith HS, Deer TR, Staats PS, et al: Intrathecal drug delivery. Pain Physician. 2008; 11(2, Suppl): S89-S104. (Pubitemid 351682080)
6. Bodnar RJ, Kest B: Sex differences in opioid analgesia, hyper-algesia, tolerance and withdrawal: Central mechanisms of action and roles of gonadal hormones. Horm Behav 2010; 58(1): 72-81.
7. Deer T, Krames ES, Hassenbusch SJ, et al.: Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an Interdisciplinary Expert Panel. Neuromodulation. 2007; 10(4): 300-328.
8. Xiao WH, Bennett GJ: Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther. 1995; 274(2): 666-672.
9. Feng ZP, Doering CJ, Winkfein RJ, et al.: Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem. 2003; 278(22): 20171-20178. (Pubitemid 36799212)
10. 2+ channel function and drug action. Trends Pharmacol Sci. 1995; 16(2): 43-49.
11. Prommer E: Ziconotide: A new option for refractory pain. Drugs Today (Barc). 2006; 42(6): 369-378.
12. Wermeling D, Drass M, Ellis D, et al.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003; 43(6): 624-636. (Pubitemid 36613121)
13. Penn RD, Paice JA: Adverse effects associated with the intrathecal administration of ziconotide. Pain. 2000; 85(1-2): 291-296. (Pubitemid 30110772)
14. Shields D, Montenegro R, Ragusa M: Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuro-modulation. 2005; 8(4): 257-263. (Pubitemid 43942736)
15. Handelsman L, Cochrane KJ, Aronson MJ, et al.: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987; 13: 293-308. (Pubitemid 17143298)
16. Huskisson EC: Measurement of pain. Lancet. 1974, 2: 1127-1131.
17. Deer TR, Kim C, Bowman R, et al.: Intrathecal ziconotide and opioid combination therapy for noncancer pain: An observational study. Pain Physician. 2009; 12(4): E291-E296.
18. Wallace MS, Kosek PS, Staats P, et al.: Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008; 9(3): 271-281. (Pubitemid 351467884)
19. Webster LR, Fakata KL, Charapata S, et al.: Open-label, multi-center study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008; 9(3): 282-290. (Pubitemid 351467885)
20. Threlkeld M, Parran TV, Adelman CA, et al.: Tramadol versus buprenorphine for the management of acute heroin withdrawal: A retrospective matched cohort controlled study. Am J Addict. 2006; 15(2): 186-191.
21. Gerra G, Zaimovic A, Rustichelli P, et al.: Rapid opiate detoxication in outpatient treatment: Relationship with naltrexone compliance. J Subst Abuse Treat. 2000; 18(2): 185-191. (Pubitemid 30123102)
22. Umbricht A, Hoover DR, Tucker MJ, et al.: Opioid detoxification with buprenorphine, Clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend. 2003; 69(3): 263-272. (Pubitemid 36293938)